Quality of life of postmenopausal women in the Arimidex, Tamoxifen, alone or in combination (ATAC) adjuvant breast-cancer trial

By Mansi Janine  

The Women's Oncology Review, Vol. 5, Iss. 3, 2005-09 ,pp. : 161-162

Informa Healthcare

Access to resources Recommend Favorite

Quality of Life of Postmenopausal Women in the ATAC (“Arimidex”, Tamoxifen, Alone or in Combination) Trial after Completion of 5 years' Adjuvant Treatment for Early Breast Cancer

By Cella David   Fallowfield Lesley   Barker Peter   Cuzick Jack   Locker Gershon   Howell Anthony  

Breast Cancer Research and Treatment, Vol. 100, Iss. 3, 2006-12 ,pp. : 273-284

Springer Publishing Company

Access to resources Recommend Favorite

The ATAC (‘Arimidex’, Tamoxifen, Alone or in Combination) Trial in Postmenopausal Women with Early Breast Cancer – Updated Efficacy Results Based on a Median Follow-up of 47 Months

By Buzdar A.  

Breast Cancer Research and Treatment, Vol. 77, Iss. 3, 2003-02 ,pp. : 295-295

Springer Publishing Company

Access to resources Recommend Favorite

Breast surgery in the ‘Arimidex, Tamoxifen alone or in combination' (ATAC) trial: American women are more likely than women from the United Kingdom to undergo mastectomy

By  

The Women's Oncology Review, Vol. 4, Iss. 4, 2004-12 ,pp. : 305-306

Informa Healthcare

Access to resources Recommend Favorite

Long-term follow-up of the randomized Stockholm trial on adjuvant tamoxifen among postmenopausal patients with early stage breast cancer

By Rutqvist Lars   Johansson Hemming   Group on behalf of the Stockholm Breast Cancer Study  

Acta Oncologica, Vol. 46, Iss. 2, 2007-01 ,pp. : 133-145

Informa Healthcare

Access to resources Recommend Favorite